Group 1 - Baron Opportunity Fund achieved a return of 4.63% in Q4 2025, outperforming the Russell 3000 Growth Index's gain of 1.14% and the S&P 500 Index's return of 2.66% [1] - For the full year, the Fund appreciated 19.73%, surpassing the benchmark's return of 18.15% and the S&P's return of 17.88% [1] - The Fund's performance was supported by moderating tariff impacts, robust corporate earnings, and continued monetary easing [1] Group 2 - The Fund focuses on significant secular growth trends such as AI, space exploration, autonomous transportation, robotics, digital commerce, media, finance, advanced therapeutics, and minimally invasive surgery [1] - Duolingo, Inc. (NASDAQ:DUOL) was highlighted as a stock of interest, with a market capitalization of $4.9 billion [2] - Duolingo's stock experienced a one-month return of -7.20% and a 52-week loss of 65.34% [2] Group 3 - The Fund decided to sell its position in Duolingo before the company reported its third-quarter earnings due to concerns over decelerating user growth [3] - Initial expectations for Duolingo's growth were based on the large opportunity in global language learning, with anticipated user growth rates exceeding 25% [3] - Research indicated a continued slowdown in user growth, leading to management's acknowledgment of growth concerns and a delay in monetization strategies [3]

Financial Data and Key Metrics Changes - Revenue in Q4 2025 was $62.5 million, a decrease of 9% compared to the prior year period, primarily due to a shift in revenue mix towards lower-priced products [19] - Gross margin was 80.6% in Q4 2025, slightly down from 80.7% in Q4 2024 [19] - Total operating expenses increased to $56.3 million in Q4 2025 from $55.7 million in Q4 2024, reflecting restructuring charges and increased litigation expenses [19] - Net loss for Q4 2025 was $9.4 million, or $0.15 per share, compared to a net loss of $0.5 million, or $0.01 per share, in Q4 2024 [20] - Full year 2025 Adjusted EBITDA loss was $3.9 million, a 64% improvement over the prior year [20] - Cash usage for the full year 2025 was $27.3 million, a 46% reduction compared to $50.5 million in 2024 [21] Business Line Data and Key Metrics Changes - The company has transitioned from a Lapiplasty-focused company to a comprehensive bunion solutions provider, launching multiple new bunion procedure innovations [4] - The new bunion systems are expected to effectively double the accessible market, targeting a significant portion of the 450,000 annual bunion procedures in the U.S. [9] - Over 25% of the surgeon base has incorporated one or more of the new bunion systems into their practice, with Q4 procedure volume growth increasing over mid-single-digit rates achieved in Q3 [11][18] Market Data and Key Metrics Changes - The foot and ankle market was reported to be unusually soft in 2025, with deferrals of cases impacting overall bunion surgical volume [26] - The company expects to capture market share despite the softness, with an anticipated increase in case volume in 2026 [26] - The outlook for full year 2026 revenue is projected to be in the range of $200 million-$212 million, representing a decline of 6%-0% compared to full year 2025 [21] Company Strategy and Development Direction - The company aims to leverage its existing customer base to drive adoption of new bunion product launches and expand its product offerings to grow wallet share [8] - The strategy includes advancing the Lapiplasty technology and introducing new products like the Lapiplasty Lightning and SpeedTMT implants [12][14] - The company plans to expand its biologics market presence with new offerings, which are expected to enhance revenue without negatively impacting margins [15][30] Management's Comments on Operating Environment and Future Outlook - Management acknowledged ongoing headwinds related to broader economic conditions and softer consumer sentiment, which are expected to persist into 2026 [5] - The company anticipates a reduction in cash usage of approximately 50% for full year 2026 compared to 2025, supported by a strong balance sheet [22] - Management expressed confidence in the strategies in place to drive market share gains and improve profitability [18] Other Important Information - The company has expanded its active surgeon base from nearly 1,300 users in 2020 to over 3,300 users in 2025, indicating strong growth in customer engagement [17] - The company plans to launch additional products in 2026 that are expected to expand its total addressable market by an estimated $300 million [16] Q&A Session Summary Question: Thoughts on the softness in the foot and ankle market - Management noted that 2025 was a softer year due to case deferrals, but they are seeing an increase in Q4 case volumes, indicating market share gains [26] Question: Impact of biologics portfolio on operating margins - Management expressed optimism that the expansion of the biologics portfolio would provide additional revenue without negatively impacting margins [30] Question: Details on new products and their development - The SuperBite screws and SpeedXM midfoot plating system have been in development for about 18 months and are expected to enhance the product offering significantly [35][36] Question: How to balance the focus of the sales force with new products - Management emphasized that the sales force is trained to focus on the bunion segment while also addressing adjacent procedures, ensuring they meet customer demands [54] Question: Long-term growth expectations - Management believes that with the expanded product portfolio and focus on the bunion market, they can achieve at least mid-single-digit growth, potentially higher with market share gains [73]

Core Insights - Encision Inc. reported a decline in revenue for its 2026 fiscal third quarter, primarily due to the replacement of its surgical procedures by robotic surgeries [1] Financial Performance - The company’s financial results indicate a continued revenue decline, which is attributed to the increasing adoption of surgical robots in the medical field [1] Technology Impact - Encision's patented Active Electrode Monitoring (AEM®) Technology is designed to prevent dangerous radiant energy burns during minimally invasive surgeries, highlighting the importance of its technology in the surgical landscape [1]

Financial Data and Key Metrics Changes - Revenue grew 21% year-over-year to $10.1 billion, with operating margins at 37% reflecting investments in R&D and manufacturing scale [10][19] - Pro forma EPS increased 22%, marking the third consecutive year of growth above 20% [19] - Free cash flow rose to $2.5 billion, up from $1.3 billion in 2024 [19] Business Line Data and Key Metrics Changes - Total procedures grew 19%, with da Vinci procedures increasing approximately 18% and Ion procedures growing 51% [7][18] - In Q4, da Vinci procedures grew 17%, with the installed base increasing by 12% to over 11,100 systems [20] - Ion platform procedures increased 44%, with the installed base up by 24% to just under 1,000 systems [20] Market Data and Key Metrics Changes - In the U.S., da Vinci procedures increased 15% to over 2 million, while international procedures grew by 23% to over 1.1 million [7] - Growth rates were 21% in Europe, 24% in Asia, and 27% in the rest of the world [7] - Total procedures outside the U.S. accounted for roughly 35% of global procedures [7] Company Strategy and Development Direction - The company focuses on four strategic priorities: launching da Vinci 5, increasing adoption of focused procedures, building industrial scale and product quality, and enhancing digital tools [5][16] - The company aims to expand its platforms and digital features while increasing adoption of focused procedures through training and market access efforts [16] Management's Comments on Operating Environment and Future Outlook - Management believes the company is in the early stages of advancing minimally invasive care, with significant long-term opportunities ahead [4] - For 2026, the company anticipates da Vinci procedure growth in the range of 13%-15%, driven by general surgery in the U.S. and international procedures [41][42] - The company expects pro forma gross profit margin to be between 67% and 68% of net revenue in 2026 [42] Other Important Information - The company placed 1,721 da Vinci systems in 2025, including 870 da Vinci 5 systems [8] - The installed base of da Vinci systems increased by 12% to just over 11,100 systems, with average system utilization increasing by 4% [20] - The company received FDA clearance for several cardiac procedures on da Vinci 5, indicating a focus on expanding into new disease states [11][52] Q&A Session Summary Question: FDA approvals for cardiac non-force feedback instruments - Management discussed the foundational aspects of supporting cardiac surgery and the importance of training pathways for minimally invasive approaches [48][50] Question: Incorporating advanced imaging features into the robotic ecosystem - Management explained that advanced imaging capabilities are being developed to improve surgical outcomes and will have associated revenue streams [54][55] Question: Expanding footprint in ASCs - Management highlighted the importance of high-quality clinical outcomes and the economic structure needed for ASCs, with a focus on lower acuity procedures [61][62] Question: Utilization and system ASPs in 2026 - Management indicated that while overall da Vinci utilization grew 4%, they are not ready to predict future utilization rates [66] Question: Gross margin and OpEx assumptions - Management outlined various dynamics affecting gross margin, including higher trade-ins and a mix of da Vinci 5 systems [72] Question: Competition in China - Management acknowledged increased competition in China but expressed confidence in their ability to compete effectively [75][76]

Core Thesis - Intuitive Surgical, Inc. (ISRG) is recognized as a global leader in robotic-assisted surgery, with a strong market position and a robust business model that supports high-margin, predictable revenue streams [2][3]. Company Overview - The da Vinci system by Intuitive Surgical has been utilized in over 17 million operations across 74 countries, establishing a significant presence in the surgical ecosystem [2]. - The company holds an estimated 60–70% market share in soft-tissue robotics, supported by a comprehensive approach that includes hospital workflows, surgeon training, and recurring revenue from instruments and services [2][3]. Financial Performance - Intuitive Surgical has achieved a 15% compound annual growth rate (CAGR) in revenues over the last decade, with nearly $10 billion in annual revenue, of which 85% is recurring [3][4]. - The company maintains gross margins near 70%, generates over $1 billion in free cash flow annually, and operates with virtually no debt [4]. - Recent performance indicates strong system placements and a 21% growth in recurring revenue, alongside stable margins despite some cost pressures [4]. Growth Drivers - Growth is driven by the expansion of the installed base, increasing procedure volumes, global reach, and ongoing product innovation, including the da Vinci 5 system and new platforms like Ion [3][4]. - Long-term trends favoring minimally invasive surgery and the expansion of procedures into new specialties are expected to support low double-digit to mid-teens growth in the future [4]. Valuation Insights - The current valuation of Intuitive Surgical is considered rich, with shares trading around 50 times earnings, suggesting limited upside from current levels [5]. - The stock is viewed as attractive primarily at lower entry points, with an accumulation target set near $380 per share to optimize risk and reward [5]. Competitive Landscape - Despite increasing competition from companies like Medtronic, CMR Surgical, and Johnson & Johnson, Intuitive Surgical's established ecosystem and regulatory approvals create a durable competitive advantage [3].